Talar Telvizian

Talar Telvizian

Auto-generated profile, based on publicly available information

Talar Telvizian

Department of Hematology and Oncology, Lankenau Medical Center, Wynnewood, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JNJad Najdi
Jad Najdi
LHLayal Hajjar
Layal Hajjar
OHOla Hadadeh
Ola Hadadeh
TTTalar Telvizian
Talar Telvizian
CDChristelle Dagher
Christelle Dagher
MEMarwan El-Sabban
Marwan El-Sabban
Matrix metalloproteinases (MMPs) are emerging as promising diagnostic and prognostic biomarkers for prostate cancer (PCa). This study explored the association between urinary exosome MMP levels and the incidence of prostate cancer. Urine samples were collected from patients undergoing prostate biopsy or prostatectomy, and from age-matched healthy controls. A total of 147 patients participated, including 37 patients who provided samples before prostatectomy, 41 patients before a biopsy that turned out positive, 21 patients before a biopsy that turned out negative, and 48 healthy controls. The study found that MMP-2 expression was similar in patients with prostate cancer and healthy controls but significantly higher in those with a negative biopsy. MMP-9 expression was elevated in patients with a positive biopsy and even higher in those with a negative biopsy. Multivariate logistic regression, adjusted for age, showed that increased MMP-2 expression was linked to a higher likelihood of a negative biopsy result (OR 1.12 [1.002,1.252], P = 0.046), while increased MMP-9 expression was associated with a higher probability of prostate cancer diagnosis (OR 1.106 [1.002,1.22], P = 0.045). These findings suggest that urinary MMP-9 levels are elevated in PCa patients, though even higher levels in biopsy-negative cases may reflect confounding factors such as benign prostatic inflammation.

8 May 2025 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
TTTalar Telvizian
Talar Telvizian
AMAlexander C May
Alexander C May
OAObed Agyei
Obed Agyei
EZErik Zeger
Erik Zeger
Primary splenic angiosarcoma is an extremely rare and aggressive vascular neoplasm associated with high rates of metastasis. A male patient in his 70s presented with thrombocytopenia. Physical examination and blood tests were non-revealing. A large splenic lesion was found on imaging, and splenectomy confirmed the diagnosis of splenic angiosarcoma. A PET scan and brain MRI showed no evidence of metastasis. The patient is now under surveillance with imaging. Primary splenic angiosarcoma presents a significant clinical challenge due to its aggressive nature and nonspecific symptoms, with outcomes typically poor despite treatment efforts. Chemotherapeutic options lack consensus due to the rarity of the disease. Most patients present with metastases, and treatment primarily involves resection, with adjuvant therapies considered based on risk factors. This case underscores the importance of considering rare malignancies in the differential diagnosis of patients presenting with thrombocytopenia and nonspecific symptoms. Early detection and prompt intervention are fundamental in improving outcomes.

13 September 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TTTalar Telvizian
Talar Telvizian
AMAlisha P. Maity
Alisha P. Maity
SKStephanie Kjelstrom
Stephanie Kjelstrom
MWMarisa Weiss
Marisa Weiss
RCRobin Ciocca
Robin Ciocca
AGArezoo Ghaneie
Arezoo Ghaneie
Hormone receptor-positive (HR+) breast cancer is the most common type among women in the United States. Multigene assays such as Oncotype DX (ODX) assess recurrence risk and chemotherapy benefit but are costly and time-consuming. This exploratory study evaluates the AI-powered PreciseBreast (PDxBR) and compares its risk scoring with established tools. This pilot study was conducted in a community health system. Female patients with newly diagnosed early-stage HR+ invasive ductal or mixed ductal/lobular carcinoma eligible for ODX testing were included. Pathology slides were analyzed using PDxBR. Results were compared with ODX and RSClin scores using Cohen’s kappa, Gwet’s AC2, and symmetry testing. Turnaround times were compared using a paired t-test. Results did not influence clinical management. Fifty patients were enrolled (mean age 61); 72% had stage IA disease. Most had invasive ductal carcinoma (94%), 6% had mixed histology, and 18% were node-positive. Agreement between PDxBR and ODX was fair (κ = 0.25, p = 0.29), with most patients classified as low risk. Agreement with RSClin was slight (κ = 0.06–0.084, p < 0.05), with no agreement beyond chance by Gwet’s AC2. Mean turnaround time was shorter for PDxBR (1.9 vs. 6.9 days, p < 0.0001). Cost was lower ($1500 vs. $4620). PDxBR confirmed the expected workflow advantages of AI-based pathology, including shorter turnaround time and lower estimated cost, but had limited concordance with ODX and RSClin. AI-based digital pathology may complement genomic assays, but larger studies with clinical outcome data are required before its role as an alternative can be established.